In line with my general bullishness about the health care sector I think now would be a good time to add to holdings of this biopharmaceutical company.
The latest price is $55 versus my original recommendation price of $43. This company has been on a roll since 1994, when you could have bought the shares for less than 50 cents; that price has been adjusted for stock splits of which there have been four so that for every share bought in 1994 there are now 16.
Its strongest business is its drugs for the treatment of AIDS, which generated revenue of $3.14bn last year out of total revenue of $4.2bn. Tests are now taking place to see whether the drugs can be used earlier to prevent the disease.
Free subscription to Shares magazine
Trials will be significant
...
